{"id":"NCT01251380","sponsor":"Ipsen","briefTitle":"Dysport® Pediatric Lower Limb Spasticity Follow-on Study","officialTitle":"A Phase III, Prospective, Multicentre, Open Label, Extension Study Assessing the Long Term Safety and Efficacy of Repeated Treatment With DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2010-12-01","resultsPosted":"2017-06-01","lastUpdate":"2022-09-28"},"enrollment":216,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cerebral Palsy","Muscle Spasticity","Children"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]}],"arms":[{"label":"Dysport","type":"EXPERIMENTAL"}],"summary":"The purpose of this research study was to determine the long term safety and efficacy of repeated treatments with Dysport® used in the treatment of lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy.","primaryOutcome":{"measure":"Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Reported in the Double Blind (DB) + Open Label (OL) Period.","timeFrame":"From baseline (Day 1) until end of study (Week 40) of Cycle 1 and up to Week 28 of Cycles 2 to 4.","effectByArm":[{"arm":"Total Dysport","deltaMin":177,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":27,"countries":["United States","Chile","France","Mexico","Poland","Turkey (Türkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":215},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Pyrexia","Pharyngitis","Cough"]}}